Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2026)
Lyell Immunopharma (LYEL) reported Capital Expenditures of $89000.0 for Q1 2026, down 42.58% on a YoY basis from $155000.0 in Q1 2025, and down 88.59% sequentially from $780000.0 in Q4 2025.
Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Capital Expenditures data on file, last reported at $89000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 42.58% year-over-year to $89000.0; the trailing twelve-month figure through Mar 2026 stood at $714000.0 (up 165.43% YoY), and the FY2025 full-year result was $780000.0, up 441.67% from the prior year.
- Capital Expenditures fell to $89000.0 in Q1 2026, from $780000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $16.1 million in Q3 2022 to a low of -$18.4 million in Q4 2022.
- A 5-year average of $295529.4 and a median of $155000.0 in 2025 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures surged 1507.24% in 2022 and slumped 211.89% in 2025, its largest moves.
- Tracing LYEL's Capital Expenditures over 5 years: stood at -$18.4 million in 2022, then surged by 114.61% to $2.7 million in 2023, then plunged by 110.28% to -$276000.0 in 2024, then soared by 382.61% to $780000.0 in 2025, then plunged by 88.59% to $89000.0 in 2026.
- Business Quant data shows LYEL's Capital Expenditures at $89000.0 in Q1 2026, $780000.0 in Q4 2025, and -$414000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | 89,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Dec 31, 2025 | 780,000.00 |
| Dec 31, 2025 | 780,000.00 |
| Sep 30, 2025 | -414,000.00 |
| Sep 30, 2025 | -414,000.00 |
| Jun 30, 2025 | 259,000.00 |
| Jun 30, 2025 | 259,000.00 |
| Mar 31, 2025 | 155,000.00 |
| Mar 31, 2025 | 155,000.00 |
| Dec 31, 2024 | -276,000.00 |
| Dec 31, 2024 | -276,000.00 |
| Sep 30, 2024 | 370,000.00 |
| Sep 30, 2024 | 370,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 2.68 Mn |
| Dec 31, 2023 | 2.68 Mn |